ChengDu ShengNuo Biotec Co.,Ltd. (SHA:688117)

China flag China · Delayed Price · Currency is CNY
21.44
-0.16 (-0.74%)
Jun 10, 2026, 3:00 PM CST
Market Cap4.72B +31.4%
Revenue (ttm)801.40M +49.4%
Net Income177.17M +119.6%
EPS0.80 +118.2%
Shares Out 220.34M
PE Ratio26.80
Forward PE22.91
Dividend0.25 (1.16%)
Ex-Dividend DateJun 5, 2026
Volume3,104,334
Open21.68
Previous Close21.60
Day's Range21.05 - 22.05
52-Week Range21.08 - 34.26
Beta0.59
Analystsn/a
Price Targetn/a
Earnings DateJul 31, 2026

About ChengDu ShengNuo Biotec

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide, somatostatin, thymopentin, carbetocin, atosiban acetate, exenatide; and leuprorelin, degarelix, cetrorelix, plecanatide, and desmopressin acetate. Che... [Read more]

Sector Healthcare
Founded 2001
Employees 1,605
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688117
Full Company Profile

Financial Performance

In 2025, ChengDu ShengNuo Biotec's revenue was 741.46 million, an increase of 62.57% compared to the previous year's 456.07 million. Earnings were 157.92 million, an increase of 215.70%.

Financial Statements